GSA Capital Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

GSA Capital Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,247	Closed	-$469K	–	1236
2020 Q1	$469K	Buy	3,247 +1,897	+141%	+$366K	0.12%	200
2019 Q4	$276K	Buy	+1,350	New	+$246K	0.03%	1080
2018 Q1	–	Sell	-26,300	Closed	-$745K	–	1885
2017 Q4	$745K	Buy	+26,300	New	+$734K	0.05%	740

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's RETA Position: Q2 2020 in Review

GSA Capital Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 3,247 shares — an estimated $469K sold.

GSA Capital Partners first reported a position in RETA in Q4 2017 and held it in 3 quarters. The position peaked at $745K in Q4 2017. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

GSA Capital Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
GSA Capital Partners sold 3,247 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $469K.
GSA Capital Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 3 quarters.
GSA Capital Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $745K in Q4 2017.
207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on GSA Capital Partners's 13F filing for Q2 2020, filed 11 Aug 2020.